Related Experiment Video
Updated: Jan 28, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia
Katrina L Ellis1, Leopoldo Pérez de Isla2, Rodrigo Alonso3
1School of Medicine, Faculty of Medicine and Health Sciences, University of Western Australia, Perth, Australia; School of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Western Australia, Perth, Australia.
Insights
Cascade screening for familial hypercholesterolemia (FH) effectively identifies individuals with elevated lipoprotein(a) [Lp(a)], a risk factor for atherosclerotic cardiovascular disease (ASCVD). Combining FH and Lp(a) testing enhances ASCVD risk detection in relatives.
Area of Science:
- Cardiovascular Genetics
- Lipid Metabolism
- Public Health Screening
Background:
- Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited conditions linked to premature atherosclerotic cardiovascular disease (ASCVD).
- While FH cascade testing is recommended, similar guidelines for elevated Lp(a) are lacking.
- This highlights a gap in screening strategies for these related genetic cardiovascular risk factors.
Purpose of the Study:
- To evaluate the effectiveness of Lp(a) testing within an existing FH cascade screening program.
- To determine if Lp(a) testing can identify individuals at higher ASCVD risk among FH relatives.
- To assess the yield of detecting elevated Lp(a) in different FH proband subgroups.
Main Methods:
- A cohort of 2,927 family members from 755 FH index cases (SAFEHEART study) underwent genetic FH and Lp(a) testing (≥50 mg/dl).
- Prevalence and detection rates of elevated Lp(a) were compared between FH relatives of probands with and without high Lp(a).
- A prospective analysis examined the association between elevated Lp(a) and ASCVD events over 5 years.
Main Results:
- Systematic screening of FH probands with elevated Lp(a) yielded 1 new case of high Lp(a) per 2.4 individuals screened.
- Opportunistic screening of FH probands without elevated Lp(a) identified 1 case per 5.8 individuals.
- Both FH and elevated Lp(a) independently increased ASCVD event risk (HRs 2.47 and 3.17, respectively).
- Individuals with both FH and elevated Lp(a) faced the highest risk (HR 4.40), independent of traditional risk factors.
Conclusions:
- Integrating Lp(a) testing into FH cascade screening is effective for identifying at-risk relatives.
- This combined approach enhances the detection of elevated Lp(a) and associated heightened ASCVD risk.
- The strategy is particularly valuable when the FH proband also has elevated Lp(a).
Background:
Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD). Cascade testing is recommended for FH, but there are no similar recommendations for elevated Lp(a).
Objectives:
This study investigated whether testing for Lp(a) was effective in detecting and risk stratifying individuals participating in an FH cascade screening program.
Methods:
Family members (N = 2,927) from 755 index cases enrolled in SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study) were tested for genetic FH and elevated Lp(a) via an established screening program. Elevated Lp(a) was defined as levels ≥50 mg/dl. The authors compared the prevalence and yield of new cases of high Lp(a) in relatives of FH probands both with and without high Lp(a), and prospectively investigated the association between elevated Lp(a) and ASCVD events among family members.
Results:
Systematic screening from index cases with both FH and elevated Lp(a) identified 1 new case of elevated Lp(a) for every 2.4 screened. Opportunistic screening from index cases with FH, but without elevated Lp(a), identified 1 individual for 5.8 screened. Over 5 years' follow-up, FH (hazard ratio [HR]: 2.47; p = 0.036) and elevated Lp(a) (HR: 3.17; p = 0.024) alone were associated with a significantly increased risk of experiencing an ASCVD event or death compared with individuals with neither disorder; the greatest risk was observed in relatives with both FH and elevated Lp(a) (HR: 4.40; p < 0.001), independent of conventional risk factors.
Conclusions:
Testing for elevated Lp(a) during cascade screening for FH is effective in identifying relatives with high Lp(a) and heightened risk of ASCVD, particularly when the proband has both FH and elevated Lp(a).
Related Concept Videos
Protein Families
Protein Families
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Gene Families
Intracellular Signaling Cascades
Rab Cascades

